期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卵巢癌DNA甲基化的研究进展 被引量：2

The research progress of DNA methylation in ovarian cancer
下载PDF
导出
摘要 卵巢癌是死亡率最高的妇科恶性肿瘤之一，其发生、发展及耐药机制与DNA甲基化关系密切。通过改变启动子CpG岛甲基化状态调控基因表达，甲基化改变相对稳定并能在血清中检测到，可以作为微创检查的生物标志。深入研究DNA甲基化作用机制将有助于卵巢癌早期诊断、辅助治疗和预后判断。 Objective DNA methylation is intimately associated with tumorigenesis, progression and chemoresistance of ovarian cancer, which is the most lethal gynecologic malignancy. It regulates the expression of genes through altered DNA methylation at CpG islands of promoter. Aberration of methylation is relatively stable. Detection of methylation biomarkers in the serum has potential as a minimally invasive detection tool. A greater understanding of the mechanism of DNA methylation in ovarian cancer will be useful for improving early diagnostic, therapeutic responsiveness and evaluation of prognosis.
作者 于歌(综述) 王晶(审校)
机构地区 哈尔滨医科大学附属第三医院
出处 《实用肿瘤学杂志》 CAS 2013年第1期81-84,共4页 Practical Oncology Journal
关键词 DNA甲基化 卵巢癌 CPG岛 DNA methylation Ovarian cancer CpG islands
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献36

  • 1A Jemal, R Siegel, Jq Xu, et al. Cancer Statistics,2010 [ J ]. CA Cancer Clin ,2010,60:277 -300.
  • 2Esteller M. Epigenetics in cancer [ J ]. N Engl J Med,2008, 358(11) :1148 -1159.
  • 3Press JZ,De LA,Boyd N ,et al. Ovarian carcinomas with ge- netic and epigenetic BRCA1 loss have distinct molecular ab- normalities [ J ]. BMC Cancer,2008,8 : 17.
  • 4Dworkin AM, Spearman AD, Tseng SY, et al. Methylation not a frequent "second hit" in tumors with germline BRCA mutations [ J ]. Faro Cancer,2009,8 : 339 - 346.
  • 5Yang I-I J, Liu VW, Wang Y, et al. Differential DNA methyla- tion profiles in gynecological cancers and correlation with clinico - pathological data[ J]. BMC Cancer,2006,6:212.
  • 6Akahira J, Sugihashi Y, Ito K, et al. Promoter methylation status and expression of TMS1 gene in human epithelial o- varian cancer[ J ]. Cancer Science,2004,95:40 - 43.
  • 7Terasawa K, Sagae S, Toyota M, et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer [ J ]. Clin Cancer Res, 2004,10:2000 - 2006.
  • 8Kaneuchi M, Sasaki M,Tanaka Y, et al. WT1 and WT1 -AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma [ J ]. Cancer, 2005,104 : 1924 - 1930.
  • 9沈文洁,邢福祺,鲁永鲜,孔令红.印迹基因LOT1在卵巢上皮性癌组织中的表达及其甲基化的研究[J].中华妇产科杂志,2007,42(5):339-340. 被引量：2
  • 10Fiegl H, Windbichler G, Mueller - Holzner E, et al. HOXA11 DNA methylation: a novel prognostic biomarker in ovarian cancer [ J ]. Int J Cancer, 2008, 123 : 725 - 729.

二级参考文献31

  • 1郭丽娜,刘彤华,孙爱军,周全.具有内分泌功能的卵巢肿瘤[J].中华病理学杂志,2004,33(3):217-220. 被引量：6
  • 2王国洪.抑制素测定的临床意义[J].标记免疫分析与临床,2004,11(4):238-240. 被引量：4
  • 3张义国.抑制素与卵巢癌[J].现代妇产科进展,1996,5(2):160-163. 被引量：4
  • 4Ciris M,Erhan Y,Zekioglu O,et al.Alinhibin alpha and beta expression in ovarian stromal tumors and their histological equivalences[J].Acta Obstet Gynecol Scand,2004;83(5):491 ～ 496
  • 5ZhengW,Lu JJ,LuoF,etal.Tumor stromaas the mainsource of inhibin production in ovarian epithelial tumors[J].Am J Reprod Immunol,2000;44(2):104～ 113
  • 6Dokras A,Habana A,Giraldo J,et al.Secretion of inhibin B druing ovarian stimulation is decreased in infertile women with endometriosis[J].Fertil Steril,2000;74(1):35 ～ 40
  • 7Burger HG,Clinical review 46; clinical utility of inhibin measurements[J].Clin Endocrinol Metab,1993;76(6):1391
  • 8Burger HG.Inhibin as a tumour marker[J].Clin Endocrinol,1994;41:151 ～ 153
  • 9Jobling T,Mamers P,Healy DL,et al.A prospective study of inhibin in granulose cell tumors of the ovary[J].Gynecol Oncol,1994;55(2):285
  • 10CookeI,BrienM,CharnockFM,etal.Inhibin as a macker for ovarian cancer[J].BrJ Cancer,1995;71(5):1046

共引文献3

同被引文献20

  • 1沈文静,郭科军,戴冬秋,王晓彩.CDH1基因异常甲基化在上皮性卵巢癌中的检测及临床意义[J].中国实用妇科与产科杂志,2007,23(7):520-522. 被引量：5
  • 2谢幸,苟文丽.妇产科学[M].8版.北京:人民卫生出版社,2013:118-119.
  • 3Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [J]. Gynecol Oncol, 2008, 108(2): 402-408.
  • 4Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analy- sis of HE4 expression in normal and malignant human tissues [J]. Mod Pathol, 2006, 19(6): 847-853.
  • 5Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tu- mor biomarker I-IE4 in patients with endometrioid adenocarcinoma of the uterus [J]. Gynecol Oncol, 2008, 110(2): 196-201.
  • 6Esteller M. Epigenetics in cancer [J]. N Engl J Med, 2008, 358(11): 1148-1159.
  • 7Jemal A,Siegel R, Xu J, et al. Cancer statistics,2010 [ J ]. CA Cancer J Clin,2010,60 (5) :277 - 300.
  • 8Feigenberg T, Clarke B, Virtanen C, et al. Molecular profi- ling and clinical outcome of high -grade serous ovarian cancer presenting with low - versus high - volume ascites [ J]. Biomed Res Int,2014 ,2014 :367103.
  • 9Beer JH, Haeberli A, Vogt A, et al. Coagulation markers pre- dict survival in cancer patients [ J ]. Thromb Haemost,2002, 88(5) :745 -749.
  • 10Diao D, Wang Z, Cheng Y, et al. D - dimer ; not just an in- dicator of venous thrombosis but a predictor of asymptomat- ic hematogenousmetastasis in gastric cancer patients [ J ]. PLoS One ,2014.9 (7) : el01125.

二级引证文献14

实用肿瘤学杂志
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部